Gene therapy for inherited retinal degenerations

Comptes Rendus - Biologies

Volumn 337, Issue 3, 2014, Pages 185-192

  Dalkara, Deniz ^a,b   Sahel, José Alain ^a,b,c,d,e,f  

^a INSTITUT DE LA VISION   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^d CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f Academie des Sciences   (France)

Author keywords

AAV; Gene therapy; Inherited retinal degenerations; Optogenetics; RdCVF; Trophic factors

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; GLIAL CELL DERIVED NEUROTROPHIC FACTOR; HALORHODOPSIN; MESSENGER RNA; MYOSIN VIIA; NEUROTROPHIC FACTOR; NEUROTROPHIN; RETINOSCHISIN; RHODOPSIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

EYE DISEASE; GENE; GENETIC ANALYSIS; IMMUNOASSAY; VIRUS;

ADENO ASSOCIATED VIRUS; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BLOOD RETINA BARRIER; CELL SURVIVAL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC DISORDER; GENOTYPE; HUMAN; HUMORAL IMMUNITY; INHERITANCE; NEUROPROTECTION; NONHUMAN; OPTOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHOTORECEPTOR; PHOTORECEPTOR OUTER SEGMENT; PIGMENT EPITHELIUM; PROTEIN EXPRESSION; RETINA DEGENERATION; RETINA GANGLION CELL; RETINITIS PIGMENTOSA; RNA INTERFERENCE; SURVIVAL FACTOR; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VISUAL ACUITY;

ADENO-ASSOCIATED VIRUS;

AAV; DÉGÉNÉRESCENCES RÉTINIENNES HÉRÉDITAIRES; FACTEURS TROPHIQUES; GENE THERAPY; INHERITED RETINAL DEGENERATIONS; OPTOGENETICS; OPTOGÉNÉTIQUE; RDCVF; THÉRAPIE GÉNIQUE; TROPHIC FACTORS;

BLINDNESS; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; HUMANS; RETINAL DEGENERATION; RNA INTERFERENCE;

EID: 84898008506     PISSN: 16310691     EISSN: 17683238     Source Type: Journal    
DOI: 10.1016/j.crvi.2014.01.002     Document Type: Short Survey

References (57)

1. A.J. Smith, J.W.B. Bainbridge, and R.R. Ali Gene supplementation therapy for recessive forms of inherited retinal dystrophies 2011 1 8 10.1038/gt.2011.161
2. S.E. Boye, S.L. Boye, A.S. Lewin, and W.W. Hauswirth A comprehensive review of retinal gene therapy Mol. Ther. 21 2013 509 519
3. J.W.B. Bainbridge et al. Effect of gene therapy on visual function in Leber's congenital amaurosis New Engl. J. Med. 358 2014 2231 2239
4. A.V. Cideciyan, T.S. Aleman, and S.L. Boye Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics 2008
5. A.M. Maguire et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis New Engl. J. Med. 358 2008 2240 2248
6. J. Bennett et al. AAV2 gene therapy readministration in three adults with congenital blindness Sci. Transl. Med. 4 2012 15 120
7. S.G. Jacobson et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years Arch. Ophthalmol. 130 2012 9 24
8. D.H. Anderson, and S.K. Fisher The relationship of primate foveal cones to the pigment epithelium J. Ultrastructure Res. 67 1979 23 32
9. A.V. Cideciyan et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement Proc. Natl. Acad. Sci. USA 110 2013 E517 E525
10. R. Herrero-Vanrell Microparticles as drug delivery systems for the back of the eye. Drug product development for the back of the eye 2011
11. S.M. Conley, and M.I. Naash Nanoparticles for retinal gene therapy Prog. Retinal Eye Res. 29 2010 376 397
12. D. Dalkara et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous Mol. Ther. 17 2009 2096 2102
13. C. Andrieu-Soler, R.A. Bejjani, and T. de Bizemont Ocular gene therapy: a review of non-viral strategies Mol. Vis. 2006
14. Z. Han, S.M. Conley, M.I. Naash, and A.A.V. Compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects Invest. Ophthalmol. Vis. Sci. 52 2011 3051 3059
15. A. Koirala, S.M. Conley, and M.I. Naash A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium Biomaterials 34 2013 7158 7167
16. X. Cai, S. Conley, and M. Naash Nanoparticle applications in ocular gene therapy Vis. Res. 48 2008 319 324
17. Z. Han, S.M. Conley, R.S. Makkia, M.J. Cooper, and M.I. Naash DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice J. Clin. Invest. 122 2012 3221 3226
18. R. Kumar-Singh Barriers for retinal gene therapy: separating fact from fiction Vis. Res. 48 2008 1671 1680
19. K.S. Balaggan, and R.R. Ali Ocular gene delivery using lentiviral vectors Gene Ther. 19 2012 145 153
20. L.H. Vandenberghe, and A. Auricchio Novel adeno-associated viral vectors for retinal gene therapy 2011 1 7
21. S. Heegaard, O.A. Jensen, and J.U. Prause Structure and composition of the inner limiting membrane of the retina Graefe's Arch. Clin. Exp. Ophthalmol. 1986
22. J. Hori, J.L. Vega, and S. Masli Review of ocular immune privilege in the year 2010: modifying the immune privilege of the eye Occult. Immunol. Inflamm. 18 2010 325 333
23. W. Li et al. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye Mol. Vis. 15 2009 267 275
24. H. Petrs-Silva et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors Mol. Ther. 17 2009 463 471
25. D. Dalkara et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous Sci. Transl. Med. 5 2013 76 189
26. S.E. Boye Transduction of the outer retina. In ARVO Meeting Abstracts 2013
27. L. Yin et al. Intravitreal injection of AAV2 transduces macaque inner retina Invest. Ophthalmol. Vis. Sci. 52 2011 2775 2783
28. H.F. Mendes, J. van der Spuy, J.P. Chapple, and M.E. Cheetham Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy Trends Mol. Med. 11 2005 177 185
29. H. Mao et al. AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa Hum. Gene Ther. 22 2011 567 575
30. F.Q. Liang et al. Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa Mol. Ther. 4 2001 461 472
31. G. Okoye et al. Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage J. Neurosci. 23 2003 4164 4172
32. P.K. Buch et al. In contrast to AAV-mediated Cntf expression AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration Mol. Ther. 14 2006 700 709
33. D. Dalkara et al. AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa Mol. Ther. 2011
34. L.H.M. Sanftner, H. Abel, W.W. Hauswirth, and J.G. Flannery Glial Cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa Mol. Ther. 4 2001 622 629
35. D.M. Lipinski, M.S. Singh, and R.E. MacLaren Assessment of cone survival in response to CNTF, GDNF, and VEGF165b in a novel ex vivo model of end-stage retinitis pigmentosa Invest. Ophthalmol. Vis. 2011
36. J. Chen et al. Bcl-2 overexpression reduces apoptotic photoreceptor cell death in three different retinal degenerations Proc. Natl. Acad. Sci. USA 93 1996 7042 7047
37. K.C. Leonard et al. XIAP protection of photoreceptors in animal models of retinitis pigmentosa PloS one 2 2007 e314
38. AAV-mediated gene transfer of human X-linked inhibitor of apoptosis protects against oxidative cell death in human, RPE, cells Invest. Ophthalmol. Vis. Sci. 52 2011 9591 9597
39. L.A. Zadro-Lamoureux, D.N. Zacks, and A.N. Baker Effects on XIAP retinal detachment-induced photoreceptor apoptosis Ophthalmol. Vis. 2009 10.1167/iovs.08-2855
40. T. Léveillard, and J.-A. Sahel Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling Sci. Transl. Med. 2 2010 16 26
41. Z.Y. Li, I.J. Kljavin, and A.H. Milam Rod photoreceptor neurite sprouting in retinitis pigmentosa J. Neurosci. 15 1995 5429 5438
42. T. Léveillard et al. Identification and characterization of rod-derived cone viability factor Nat. Genet. 36 2004 755 759
43. Y. Yang et al. Transplantation of photoreceptor and total neural retina preserves cone function in P23H rhodopsin transgenic rat PloS one 5 2010 e13469
44. Y. Yang et al. Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa Mol. Ther. 17 2009 787 795
45. L. Byrne Engineered adeno-associated viral vectors for gene therapy in the retina 2011
46. V. Busskamp, S. Picaud, J.A. Sahel, and B. Roska Optogenetic therapy for retinitis pigmentosa Gene Ther. 19 2012 169 175
47. A. Bi et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration Neuron 50 2006 23 33
48. P.S. Lagali et al. Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration Nat. Neurosci. 11 2008 667 675
49. V. Busskamp et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa Science 329 2010 413 417
50. C.L. Cepko Emerging gene therapies for retinal degenerations J. Neurosci. 32 2012 6415 6420
51. J.G. Flannery, and K.P. Greenberg Looking within for vision Neuron 50 2006 1 3
52. M.M. Doroudchi et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness Mol. Ther. 2009 1 10
53. D. Hicks, and J. Sahel The implications of rod-dependent cone survival for basic and clinical research Invest. Ophthalmol. Vis. Sci. 1999
54. A.H. Milam, Z.Y. Li, and R.N. Fariss Histopathology of the human retina in retinitis pigmentosa Prog. Retinal Eye Res. 17 1998 175 205
55. 2+-permeable channel rhodopsin CatCh Nat. Pub. Group 14 2011 513 518
56. J.Y. Lin, P.M. Knutsen, A. Muller, D. Kleinfeld, and R.Y. Tsien ReaChR: a red-shifted variant of channel rhodopsin enables deep transcranial optogenetic excitation Nature Neurosci. 16 2013 1499 1508
57. S.G. Jacobson, A. Sumaroka, X. Luo, and A.V. Cideciyan Retinal optogenetic therapies: clinical criteria for candidacy Clin. Genet. 84 2013 175 182